Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma

Clinical trial NCT07339488 · RECRUITING

Trial details

NCT number: NCT07339488
Sponsor: Chuangzhen Chen
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Borderline Resectable Carcinoma Unresectable Cancer Esophageal Squamous Cell Carcinoma (ESCC)Immune Checkpoint Inhibitor Chemotherapy Radiotherapy Tislelizumab

Start date: 2025-12-05
Primary completion: 2028-11-01
Enrollment: 43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.